$15.21
-0.85%Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Last Annual Value
-175.75M
3-Year CAGR
-12%
5-Year CAGR
-43%
10-Year CAGR
-29%
| Company | Operating Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Cullinan Therapeutics, Inc. NASDAQ:CGEM | -175.75M | N/A | N/A | N/A | |
![]() Varex Imaging Corporation NASDAQ:VREX | 41.70M | -27.3% | -14.7% | N/A | |
![]() CeriBell, Inc. NASDAQ:CBLL | -40.81M | N/A | N/A | N/A | |
![]() Enhabit, Inc. NYSE:EHAB | 70.70M | 13.5% | -10.5% | N/A | |
![]() Standard BioTools Inc. NASDAQ:LAB | -74.35M | N/A | N/A | N/A | |
![]() Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | -206.44M | N/A | N/A | N/A | |
![]() RAPT Therapeutics, Inc. NASDAQ:RAPT | -83.30M | N/A | N/A | N/A | |
![]() Omeros Corporation NASDAQ:OMER | -116.09M | N/A | N/A | N/A |
Continue your CGEM research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.